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Background/aim: This study is aimed to investigate the effects of vitamin D levels on sugammadex and neostigmine reversal times.
Material and methods: Eighty patients between the ages of 18 and 65 years, with ASA I-III status who were undergoing surgery under
general anesthesia were included in the study. A double blind fashion was used to randomly divide all the patients into two groups. At
the end of the operation, sugammadex 2 mg/kg was administered to one group (Group sugammadex) and atropine and neostigmine
was administered to the other group (Group neostigmine) intravenously. In the data analysis stage, the group was divided into two
subgroups according to sugammadex and group neostigmine in itself, with vitamin D levels above and below 30 ng/mL. Statistical
analysis was performed on these 4 groups (Group neostigmine and vitamin D < 30 ng/mL), (Group neostigmine and vitamin D ≥ 30
ng/mL), ( Group sugammadex and vitamin D < 30 ng/mL), (Group sugammadex and vitamin D ≥ 30 ng/mL).
When two responses to train of four (TOF) stimulation were taken, the following times were recorded until extubation phase. The time
until TOF value 50%, 70%, 90%, and extubation were recorded.
Results: There were statistically significant differences between Group sugammadex and vitamin D < 30 ng/mL and Group sugammadex
and vitamin D ≥ 30 ng/mL (P = 0.007) for extubation times and 50% TOF reach times (P = 0.015). However, there was no difference
observed between Group neostigmine and vitamin D < 30 ng/mL and Group neostigmine and vitamin D ≥ 30 ng/mL (P = 0.999).
Conclusion: Vitamin D deficiency is important for anesthesiologists in terms of muscle strength and extubation time. Vitamin D
deficiency seems to affect sugammadex reverse times but seems not to affect neostigmine reverse times. This conclusion needs further
studies.
Key words: Anesthesia, vitamin D, muscle relaxation, sugammadex, neostigmine, neuromuscular blocker

1. Introduction
Vitamin D is essential for intestinal calcium absorption
and for maintaining calcium homeostasis. Calcium
draws on the release of acetylcholine from the motor
nerve terminal and increases the excitation–contraction
coupling in the muscle. In addition, calcium plays an
important role for contraction in skeletal muscles [1].
Vitamin D refers to vitamin D2 (ergocalciferol) or vitamin
D3 (cholecalciferol). Vitamin D3 is made in the skin or
obtained in the diet (D2 or D3), it enters the circulation
and is bound to vitamin D binding protein. This complex
is transported to the liver and after hydroxylation
becomes 25-hydroxyvitamin D (25[OH] D). Then in
kidney, it is hydroxylated by 1- alfa hydroxylase and takes
the form of 1,25-dihydroxyvitamin D (1,25[OH] D).
Vitamin D binding protein and 1,25-dihydroxyvitamin

D binds with each other and vitamin D enters the
target cells. In the target cell cytoplasm vitamin D binds
with vitamin D receptor and enters the nucleus. In
the nucleus vitamin D and retinoic acid heterodimers
increase the transcription of vitamin D-dependent genes
important for bone metabolism and calcium absorption
[2]. Anticholine esterases show their effect by inhibiting
acetylcholinesterase and butyrylcholinesterase by
prolonging the existence of acetylcholine at the motor endplate [3]. Neostigmine is the most preferred anticholine
esterase drug [4]. Sugammadex forms complexes with
steroidal neuro-muscular blocking agents (NMBAs)
(rocuronium > vecuronium ≫ pancuronium) and helps in
the rapid removal of free rocuronium [5]. Neuromuscular
transmission is clinically monitored using the train-offour (TOF) ratio, which is the quotient between twitch
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tension produced by the fourth (T4) and by the first (T1)
stimulus within a TOF stimulation at 2 Hz.
We have started to arouse curiosity among
anesthesiologists who work with muscle relaxant agents
as to whether the changes in vitamin D levels are among
the factors. In the literature, we did not encouter any study
for neuromuscular agent reverse durations and vitamin
D levels. Moreover, there is no study in the literature
reporting the effect of vitamin D levels on the onset and
return of neuromuscular blocker agents by the use of TOF
ratio. This study is aimed to investigate the effect of vitamin
D levels on sugammadex and neostigmine reversal times.
2. Materials and methods
This prospective, randomized, observational study was
carried out in the same center after the approval of the
School of Medicine of Düzce University by the ethics
committee of noninvasive research (Düzce University,
School of Medicine, Ethics Committee of Noninvasive
clinical research approval for application Date: 11.10.2013,
Decision Number: 2013/439) and was done by the
Anesthesiology Department in the same center. This
study was registered to the ClinicalTrials.gov (Identifier:
NCT03734250).
The inclusion criteria were to be between 18 and 65
years old, American Society of Anesthesiologists (ASA)
I-III status, and operated for elective surgery under general
anesthesia. The patients with hypothermia, neuromuscular
diseases, hypothyroidism, hyperthyroidism, diabetes
mellitus, and electrolyte imbalance were excluded. Written
informed consent was taken from all of the patients.
2.1. Anesthesia management
In the operating room, all the patients were monitored
using a standard monitoring procedure (heart rate,
noninvasive arterial pressure, pulse-oximetry, end tidal
carbon dioxide) and neuromuscular block monitoring
were performed. After patients had an intravenous line
performed in the back of the hand with a 20 gauge, first 10
mL blood samples were taken and then intravenous fluids
were administered. The 25-hydroxyvitamin D (25(OH)
Vitamin D ELISA kit, abcam, UK), calcium, magnesium,
phosphorus and parathormone levels were measured in
the blood samples. A double blind fashion was used to
randomly divide all the patients into two groups: (Group
sugammadex; n = 42), (Group neostigmine; n = 42).
Neuromuscular monitoring was performed to all
patients by connecting to a kinemyograph, which placed
the neuromuscular transmission (NMT) module (E-NMT
module, GE Healthcare Finland Oy, Helsinki, Finland) on
the patients’ adductor pollicis muscle before the induction
of anesthesia. Patients’ body temperatures were maintained
within 35–37 °C. All the patients received midazolam
2 mg intravenously for premedication. All the patients
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were received propofol 2 mg/kg and fentanyl 1 µg/kg.
Subsequently, propofol was given at the beginning of the
operation and TOF values were recorded as basal values
(TOFbasal) and during the operation. TOF stimulation
started at 1 Hz intervals at a frequency of 2 Hz in 1-min
intervals. The initial values determined were recorded
as the baseline TOF values and rocuronium 0.5 mg/kg
(Esmeron amp, Organon, Holland) was administered
intravenously, which was calculated for ideal body weight.
The time to complete the disappearance of response to
TOF stimulation was recorded as T0 and endotracheal
intubation was performed.
Anesthetic maintenance was proven by 50% oxygen,
50% air, and sevoflurane 2% via endotracheal tube.
Remifentanil hydrochloride (Ultiva flk, Aspen Pharma
Trading Limited, Ireland) infusion was administered
0.05–1 µg/kg / h intravenously. The muscle relaxant was
administered in repeated doses as 10 mg of rocuronium
when a 2-point response to TOF was received (Posttetanic
count (PTC) < 10).
The total muscle relaxant amounts were recorded.
Patients were divided into two groups randomly
and sugammadex (Group sugammadex; n = 42)
and neostigmine (Group Neostigmine; n=42 ) were
administered intravenously. At the end of the surgery:
when two responses were achieved from TOF stimulation,
sugammadex sodium 2 mg/kg (Bridion flk, Merck Sharp
& Dohme, U.K) or neostigmine 0.05 mg/kg (Neostigmin
amp, Adeka, Turkey) and Atropine 0.015 mg/kg (Atropine
sulphate, Galen, Turkey) per kg body weight were
performed to the patient. Data were recorded as time
to reach 50%, 70%, 90% TOF values and extubation.
In the data analysis stage, each group was divided into
two subgroups according to sugammadex and group
neostigmine in itself, with vitamin D levels above and
below 30 ng/mL. Statistical analysis was performed on
these four groups. (Group neostigmine and vitamin D <
30 ng/mL), (Group neostigmine and vitamin D ≥ 30 ng/
mL), (Group sugammadex and vitamin D < 30 ng/mL),
(Group sugammadex and vitamin D ≥ 30 ng/mL).
TOF0: The time between rocuronium administration
and TOF disappearance.
TOF0.5: The time until the TOF value reached 50%.
TOF0.7: The time until the TOF value reached 70%.
TOF0.9: The time until the TOF value reached 90%.
TOFext: Time to extubation.
TOFbasal: TOF values which measured after propofol
administration.
Extubation criteria: Patients who were able to open
their eyes with spontaneous breathing, had a tidal
volume 10 mL/kg, according to ideal body weight during
spontaneous breathing, pulse oximetry values above 95%,
ability to head lift for 5 s, and TOF values above 90%.
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2.2. Labarotory protocol
Blood samples were centrifuged at 2000 rpm for 10 min
in a refrigerated centrifuge to separate serum samples. All
samples were stored at –70 °C until they were analyzed.
Serum total 25-hydroxyvitamin D assay was performed
using ELISA kits.
2.3. Sample size and power analysis
The proposed sample size was calculated via power
analyses using GPower 3.1 software. Sample size of 20 was
determined for each group with a priori power analyses,
according to the effects size, power analysis and sample
size test for medium effect size=0.45 alpha=0.05 and test
power of 80%. Although a minimum of 20 participants per
condition is recommended, 21 participants are assigned
in each group to account for potential erroneous or other
unexpected problems [6].
2.4. Statistical analysis
Statistical analyses were performed with the SPSS v.22
package program and the significance level was accepted
as P < 0.05. Normal distribution of the TOF variables was
checked with the Kolmogorov–Smirnov test (statistic; P
for basal, 50%, 70%, 90% extubation and disappearance
of TOF values and 0.954; 0.189, 0.974; 0.620, 0.969; 0.476,
0.899; 0.069, 0.973; 0.596; and 0.959; 0.266, respectively). As
normal distribution of variables was ensured, we continued
data analysis with parametric tests. The independent
samples t-test for two variables was used for comparison of
continuous variables. For categorical variables, the Pearson
Chi-square test was used. Repeated measures ANOVA was
used to examine the interaction between the drug groups
and TOF measurement time. Coeffects of drug groups and
vitamin D subgroups were examined by two-way analysis
of variance (ANOVA). Repeated measures ANOVA, one of
the three-factor differentials, was used to examine the TOF
measurement time interaction of drug effects and vitamin
D subgroups’ concerted effects.
3. Results
Although there were no statistically significant differences
in age, body mass index (BMI), and height parameters

between the sugammadex group and neostigmine group, it
was observed that the operation period of the neostigmine
group was longer (P = 0.031; Table 1).
3.1. Comparison by group and vitamin D level
Based on the variation of vitamin D (25), we formed two
subgroups < 30 ng/mL and ≥ 30 ng/mL. Statistical analysis
was performed on these four groups: (Group neostigmine
and vitamin D < 30 ng/mL, n=31), (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11), (Group sugammadex
and vitamin D < 30 ng/mL, n=37), (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5).
The most important problem here was that the
number of patients in the vitamin D ≥ 30 ng/mL group
and the number of patients in the quadruple group were
unbalanced (As we mentioned above).
For both groups, the main effect (The difference
between the groups in terms of mean age does not change
according to whether vitamin D is low or high.) (P =
0.671) and the low/high vitamin D group main effect (P =
0.611) were not significant. All the groups were evaluated
as homogeneous and there was no difference in age.
The calcium, magnesium, phosphor levels, and the
interaction between the groups and vitamin D status were
given in Table 2.
3.2. Comparison of TOF values
(Group neostigmine and vitamin D < 30 ng/mL, n=31),
(Group neostigmine and vitamin D ≥ 30 ng/mL, n=11),
(Group sugammadex and vitamin D < 30 ng/mL, n=37),
(Group sugammadex and vitamin D ≥ 30 ng/mL, n=5).
3.2.1. Basic measurement
There was no difference between Group neostigmine and
vitamin D < 30 ng/mL, n=31 and Group neostigmine and
vitamin D ≥ 30 ng/mL, (P = 0.999).
There was no difference between Group sugammadex
and vitamin D < 30 ng/mL, n=31 and Group sugammadex
and vitamin D ≥ 30 ng/mL, (P = 0.999).
3.2.2. 50% measurement
There was no difference between (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11), (P = 0.999).

Table 1. There is no difference of the demographic data between the two groups. Operation time is
longer at neostigmine administration group than sugammadex administration group.
Neostigmine
(n=42)

Sugammadex
(n=42)

Male

21 (50%)

27 (64.3%)

Female

21 (50%)

15 (35.7%)

Age (year)

36.6 ± 13.8

38.5 ± 12.2

0.520

Body mass index (kg/m2)

25.8 ± 6.1

27.9 ± 5.6

0.094

Operation time spent (minute)

93.1 ± 43.9

74.7 ± 31.5

0.031

P
0.186
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Table 2. Calcium, magnesium, phosphor, and parathormone levels of the groups.* Phosphor
levels are higher in group sugammadex.
Group
Neostigmine (n=42)

Group
Sugammadex (n=42)

P

Calcium (mg/dL)

8.7 ± 0.9

9.1 ± 1.1

0.073

Magnesium (mg/dL)

1.9 ± 0.3

2.0 ± 0.2

0.187

Phosphor (mg/dL)

2.8 ± 0.6

3.1 ± 0.7

0.016*

Parathormone (pg/mL)

72.6 ± 35.0

63.6 ± 28.7

0.204

There was a significant statistical difference between
(Group sugammadex and vitamin D < 30 ng/mL, n=37)
and (Group sugammadex and vitamin D ≥ 30 ng/mL, n=5),
(P = 0.015).
There was no difference between (Group neostigmine
and vitamin D < 30 ng/mL, n=31) and Group sugammadex
and vitamin D < 30 ng/mL, n=37) (P = 0.999).
There was no difference between (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.987).
3.2.3. 70% measurement
There was no difference between (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and (Group neostigmine and
vitamin D ≥ 30 ng/mL, n=11) (P = 0.999).
There was no difference between (Group sugammadex
and vitamin D < 30 ng/mL, n=37) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5), (P = 0.990).
There was a significant statistical difference between
(Group neostigmine and vitamin D < 30 ng/mL, n=31) and
(Group sugammadex and vitamin D < 30 ng/mL, n=37) (P
< 0.001).
There was no difference between (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.999).
3.2.4. 90% measurement
There was no difference between (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and (Group neostigmine and
vitamin D ≥ 30 ng/mL, n=11) (P = 0.999).
There was no difference between (Group sugammadex
and vitamin D < 30 ng/mL, n=37) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.990).
There was a significant difference between (Group
neostigmine and vitamin D < 30 ng/mL, n=31) and (Group
sugammadex and vitamin D < 30 ng/mL, n=37) (P < 0.001).
There was no difference between (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.992).
3.2.5. Extubation measurements
There was no difference between (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) (P = 0.999).
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There was a significant difference between (Group
sugammadex and vitamin D < 30 ng/mL, n=37) and
(Group sugammadex and vitamin D ≥ 30 ng/mL, n=5)
(P = .0.007) There was a significant difference between
(Group neostigmine and vitamin D < 30 ng/mL, n=31)
and (Group sugammadex and vitamin D < 30 ng/mL,
n=37) (P = 0.002).
There was no difference between (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.982).
3.2.6. T0 measurements
There was no difference between (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) (P = 0.999).
There was no difference between (Group sugammadex
and vitamin D < 30 ng/mL, n=37) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.999).
There was no difference between (Group neostigmine
and vitamin D < 30 ng/mL, n=31) and Group sugammadex
and vitamin D < 30 ng/mL, n=37) (P = 0.999).
There was no difference between (Group neostigmine
and vitamin D ≥ 30 ng/mL, n=11) and (Group sugammadex
and vitamin D ≥ 30 ng/mL, n=5) (P = 0.999).
4. Discussion
It is also a major problem to achieve postoperative muscle
weakness and to maintain the respiratory functions at least
at the level of the preoperative status. Optimization and
prevention of the factors that affect the muscle contraction
is crucial for the anesthesiologist at the preoperative,
perioperative, and postoperative periods. Routine
reversal of neuromuscular blockade is common in many
countries after surgery under general anesthesia because
of the prevention of postoperative residual neuromuscular
recurarization [7].
We observed that sugammadex reverse times were
(especially TOF %50 reaching times and extubation times)
prolonged, but there was no change in the neostigmine
group with vitamin D below 30 ng/mL. This result
constitutes our primary outcome. This important finding
could have a role in the ‘cannot intubate, cannot ventilate’
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situation, a scenario where anticholinesterases have no
effect.
Vitamin D is transformed from 7-dehydrocholesterol
into provitamin D3 under ultraviolet rays on the skin.
Provitamin D3 turns into vitamin D3. Serum vitamin D is
bound to the bound protein and transported to the liver.
25 (OH) D3 is formed by hydroxylation in the liver and
it becomes 1,25 dihydroxy vitamin D in the kidneys. This
form is the biologically active form of vitamin D [8].
The majority of circulating vitamin D is in the form of
25 (OH) D3. Serum 25 (OH) D3 levels were 1000 higher
than 1.25 vitamin D levels; therefore, it is recognized as
the most appropriate indicator in determining the level of
vitamin D. The active form of 1,25 dihydroxy vitamin D
has a half-life of 4-6 h [8]. The evidence indicated that 1,25
dihydroxy vitamin D activates severe secondary pathways
in the muscle cell by binding to the membrane receptor. It
increases calcium uptake through both calcium-activated
calcium channels and calcium-dependent calcium
channels within minutes [9].
Vitamin D increases the serum calcium level by the
nuclear vitamin D receptor (VDR) [10]. VDRs are found
in the muscle tissues. Vitamin D effects and improves by
direct effect on muscle tissues itself [11,12]. Vitamin D
deficiency affects the faster and stronger type 2 muscle
fibers. Hypovitaminosis D impairs neuromuscular
coordination [11,12]. Most circulating 25 (OH) D3
and 1,25 dihydroxy vitamin D are transported in the
blood bound with vitamin D binding protein (80–90%)
and albumin (10–20%), only a small fraction is free or
unbound [13].
Adequacy of vitamin D levels were defined as a result
of various observational studies and analyses with 25 (OH)
D3 levels in the serum being above 30 ng/mL (75 nmol/L).
Vitamin D deficiency was reported as 21–29 ng/mL (52-72
nmol/l) in 25 (OH) D3 levels in the serum [14].
Neostigmine 0.004–0.007 µg/kg has an onset action
within 1 min its peak effect does not occur for 9 min [15].
The advised sugammadex dose for reversal of a moderate
NMB is 2 mg/kg and sugammadex 4 mg/kg for reversal of a
deep NMB. With these doses, a TOF-ratio ≥0.9 is achieved
in about 2 min (reversal of moderate NMB) and 1.6–3.3
min (deep NMB) [16]. In contrast, it takes on average 12.8
and 48.8 min to reach a TOF-ratio ≥0.9 when neostigmine
0.05–0.07 mg/kg is used for the reversal of a moderate and
deep NMB, respectively [16].
Suy and colleagues examined the efficacy of
sugammadex 0.5 and 4 mg/kg to reverse modarate
neuromuscular block induced by rocuronium group.
They found that reappearance of T2, 31.8 min after
placebo compared with 3.7 and 1.1 min after sugammadex
administration 0.5 and 4 mg/kg respectively [17].
Flocton et al. studied 84 patients who received either

rocuronium 0.6 mg/kg and sugammadex 2 mg/kg or
cisatracurium 0.15 mg/kg and neostigmine 50 µg/kg to
compare sugammadex for the reversal of rocuroniuminduced block with that of neostigmine-glycopyrrolate
for cisatracurium-induced block. They found that the
time recovery of the TOF ratio to 0.9 was faster with
sugammadex (2.0 min) than with neostigmine (8.8 min)
(P < 0.0001) [18].
In our previous study to compare the time of
antagonism and effect of sugammadex (2 mg/kg) which is
used for antagonism of rocuronium 0.6 mg/kg on diabetic
(n=21) and nondiabetic patients (n=20), we found that
extubation time (time from sugammadex administration
to TOF ratio reaching 0.9) was 434.6 ± 857.1 [205 (67–
4120)] s in diabetics and 250.4 ± 108.4 [247 (106–462)]
seconds in nondiabetics (P = 0.948) [19].
In our study we found that TOF-ratio 0.9 reach time
(437 ± 282 s) for (Group neostigmine and vitamin D < 30
ng/mL, n=31 ), (476 ± 258 s) for (Group neostigmine and
vitamin D ≥ 30 ng/mL, n=11). We also found that TOFratio 0.9 reach time (151 ± 117 s) for (Group sugammadex
and vitamin D < 30 ng/mL, n=37 ), (313 ± 413 s) for
(Group sugammadex and vitamin D ≥ 30 ng/mL, n=5)
in our study. There is no difference found statistically for
TOF-ratio 0.9 reach time between both two groups.
Sugammadex encapsulates the rocuronium and
separates it from the receptor. When we examined our
results, although the vitamin D levels below 30 ng/mL
were different in number, the TOF 50% group (P = 0.015)
and extubation (P = 0.007) were statistically significantly
prolonged in the (Group sugammadex and vitamin D < 30
ng/mL, n=37) (Figures 1 and 2).
It is noteworthy that this difference is due to elongation
in reaching the target at low vitamin D levels, but that
there is no difference in neostigmine. We believe that more
comprehensive studies with more patients are needed in
this area. Studies showing that muscle weakness due to
vitamin D deficiency, especially in proximal muscles and
vitamin D supplementation have improved and constitute
the main supporting base of our study [20–22]. Therefore,
we can foresee that the muscle relaxation reversal agent
can be affected by the mode of action and the reverse
duration of vitamin D levels instead.
Our secondary outcome is the effect of low vitamin
D levels on rocuronium time to TOF disappearance. We
found that there was also no difference between the groups
in terms of the time until the muscle relaxant was given
and disappearance of TOF (TOF0) during the induction
of anesthesia.
In conclusion, vitamin D deficiency is an important
factor for anesthesiologists in terms of muscle strength and
extubation time. In our study vitamin D deficiency seems
to have prolonged the sugammadex extubation times
and 50% TOF reach times but not effect on neostigmine
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Figure 1. The graphics of the neostigmine (Group neostigmine and vitamin D
≥ 30 ng/mL, n=11) and sugammadex (Group sugammadex and vitamin D ≥ 30
ng/mL, n=5) when vitamin D status is equal or above 30 ng/mL.

Figure 2. The graphics of the neostigmine (Group neostigmine and
vitamin D < 30 ng/mL, n=31) and sugammadex (Group sugammadex and
vitamin D < 30 ng/mL, n=37) when vitamin D status is under 30 ng/mL.

reverse times. We think that more comprehensive studies
with vitamin D replacement will give clearer results in this
area in the future.
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